<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418184</url>
  </required_header>
  <id_info>
    <org_study_id>PS-Omega3-2</org_study_id>
    <nct_id>NCT00418184</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzymotec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzymotec</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to determine whether an oral administration of
      Phosphatidylserine-Omega3 would significantly improve the clinical symptoms of children
      suffering from ADHD. Both the behavior and the academic achievements aspects will be
      evaluated. In addition, we intend to measure side-effects and adverse events and to examine
      the possible correlation between biochemical and behavioral alterations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center, double-blind, randomized, placebo-controlled 15-weeks duration
      trial to assess safety and efficacy of Phosphatidylserine-Omega3 in children diagnosed with
      ADHD, according to the DSM-IV. Following screening, the subjects will be randomized to one of
      two treatment groups:Phosphatidylserine-Omega3 or placebo, in a 2:1 manner. This will be
      followed by an open-label extension, in which Phosphatidylserine-Omega3 will be administered
      to all eligible participants.

      Primary measures of attention and behavior will be evaluated using Conners Rating Scale (CRS)
      teacher- rating scales. As a secondary endpoint, the attention and behavior will be measured
      by CRS and strength and difficulties questionnaires (SDQ) parental- and SDQ teacher-rating
      scales, assessment a continuous performance test (TOVA), and parental Child Health
      questionnaire (CHQ). Improvement in ADHD symptoms will be evaluated by Clinical Global of
      Impression - Improvement (CGI-I). Finally, tolerability will be monitored using Barkley Side
      Effects Rating Scale (SERS) and biochemical parameters, such as fatty acid profile and
      monoamines metabolites will be assessed as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conners Rating Scale - School Version</measure>
    <time_frame>change from baseline in conners raiting scale at 15 weeks</time_frame>
    <description>A questionnaire that assesses symptoms of ADHD in children and adolescents according to the DSM-IV guidelines. It consists of questions on classroom behavior. Based on the questionnaire results, subscales and global indexes are calculated, including restless-impulsive index, emotional lability index and hyperactive/impulsive subscale. The lowest scale score is 40 (best)and the highest is 90 (worse). Usually, a score below 62 is considered normal and a score above 62 is considered abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conners Rating Scale - Home Version</measure>
    <time_frame>change from baseline in conners raiting scale at 15 weeks</time_frame>
    <description>A questionnaire that assesses symptoms of ADHD in children and adolescents according to the DSM-IV guidelines. It consists of questions on the childs home behavior. Based on the questionnaire results, subscales and global indexes are calculated, including restless-impulsive index, emotional lability index and hyperactive/impulsive subscale. The lowest scale score is 40 (best)and the highest is 90 (worse). Usually, a score below 62 is considered normal and a score above 62 is considered abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength and Difficulties Questionnaires - School Version</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength and Difficulties Questionnaires - Home Version</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test of Variables of Attention (TOVA)</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Health Questionnaire (CHQ)- Parent-completed Form 50</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and Red Blood Cells Fatty Acid Profile</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Monoamines Metabolism</measure>
    <time_frame>on week 0, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Essential Fatty Acid (EFA)-Deficiency Symptoms</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barkley Side Effects Rating Scale (SERS)</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Counts</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Parameters in Blood - Liver Functions (SGPT, SGOT, Total Bilirubin), Kidney Functions (BUN, Creatinine), Na, K, Cl, Ca</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile (Cholesterol, HDL, Triglycerides)</measure>
    <time_frame>on weeks 0,15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Attention Deficit/Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Phosphatidylserine-Omega3</intervention_name>
    <description>Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colored cellulose tainted with fishy odor</intervention_name>
    <description>as arm 1</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parental written informed consent.

          2. Having a teacher that is familiar with the child and parent and willing to
             participate.

          3. Age: 13≥ years ≥6

          4. Gender: male and female

          5. Diagnosis: ADHD diagnosed by:

             Teacher-rated Attention-Deficit/ Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV)
             School Version at least 1.5 standard deviations (SD) above the norm for the patient's
             age and gender, Confirmed assessment by Schedule for Affective Disorders and
             Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL),

          6. Clinical Global Impression of Severity of illness (CGI-S) rating of 4 or higher
             (moderately ill or worse),

          7. Language: Subjects, parents, and teachers must be able to read, write and speak Hebrew

          8. Normal weight and height according to the Israeli standards

          9. Attending full-time to school.

        Exclusion Criteria:

          1. Females who had reached menarche and presented three regular menstrual cycles; the
             definition of regular menstrual cycles: an average length of the cycle between 22 and
             41 days, either none or a single cycle with a length less than 22 or more than 41 days
             during the past year

          2. History or current diagnosis of any serious systemic (e.g., diabetes,
             hyper/hypothyroidism, etc.) or neurological condition (e.g., epilepsy, brain tumors,
             etc.)

          3. Failed to respond to 2 or more adequate courses (dose and duration) of stimulant
             therapy for ADHD

          4. Pervasive developmental disorder or Non-verbal Learning Disability

          5. Schizophrenia, or other psychotic disorders (DSM-IV axis I)

          6. Any evidence of suicidal risk, any current psychiatric comorbidity that required
             psychiatric pharmacotherapy

          7. History of alcohol or substance abuse as defined by DSM-IV criteria

          8. Consumption of &gt;250 mg/day of caffeine

          9. Blindness

         10. History of allergic reactions or sensitivity to marine products (fish and seafood),
             soy or corn as well as any illness which may jeopardize the participants health or
             limit their successful trial completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham Weizman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of the Research Department, Geha Mental Health Center, Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ADHD Unit</name>
      <address>
        <city>Petach-Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>November 30, 2009</results_first_submitted>
  <results_first_submitted_qc>February 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2010</results_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <name_title>Manor Yonatan</name_title>
    <organization>Enzymotec LTD</organization>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>inattentive</keyword>
  <keyword>impulsive</keyword>
  <keyword>hyperactive</keyword>
  <keyword>poor academic performance</keyword>
  <keyword>poor self-discipline</keyword>
  <keyword>low self-esteem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children at the age of 6-13 years were screened at the “Geha mental health center”, Israel, for participation in the study. Recruitment of participants was achieved by vast advertisement in newspapers, internet and in practitioners clinics. Participants enrollment period March 2007 to March 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PS Omega 3 Conjugate</title>
          <description>The daily dosage consisted of 4 capsules of PS-Omega3, providing 300 mg Phosphatidylserine per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double-blind: Cellulose (4 capsules per day). Open-label: PS-omega3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102">3 were not included due to low compliance in the double blind phase, 5 didn't want to participate.</participants>
                <participants group_id="P2" count="48">1 was not included due to low compliance in the double blind phase, 3 didn't want to participate.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97">5 dropped out</participants>
                <participants group_id="P2" count="43">5 dropped out</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PS Omega 3 Conjugate</title>
          <description>The daily dosage consisted of 4 capsules of PS-Omega3, providing 300 mg Phosphatidylserine per day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double-blind: Cellulose (4 capsules per day). Open-label: PS-omega3</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.10" spread="1.89"/>
                    <measurement group_id="B2" value="9.24" spread="1.77"/>
                    <measurement group_id="B3" value="9.15" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression of Severity (CGI-S)</title>
          <description>The CGI is an observer-rated scale that measures illness severity.The clinician evaluates the patient relative to his past experience with other patients with the same diagnosis.The ratings of CGI-S are: 1 = not ill at all, 2 = a borderline case, 3 = only mildly ill, 4 = moderately ill, 5 = seriously ill and 6 = extremely seriously ill.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderately ill (score 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seriously ill (score 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely seriously ill (score 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Conners Rating Scale - School Version</title>
        <description>A questionnaire that assesses symptoms of ADHD in children and adolescents according to the DSM-IV guidelines. It consists of questions on classroom behavior. Based on the questionnaire results, subscales and global indexes are calculated, including restless-impulsive index, emotional lability index and hyperactive/impulsive subscale. The lowest scale score is 40 (best)and the highest is 90 (worse). Usually, a score below 62 is considered normal and a score above 62 is considered abnormal.</description>
        <time_frame>change from baseline in conners raiting scale at 15 weeks</time_frame>
        <population>The analysis includes per-protocol (PP) population. Out of the 162 children who completed the study, 15 children were excluded from PP analysis due to low compliance or protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>PS Omega 3 Conjugate</title>
            <description>The daily dosage consisted of 4 capsules of PS-Omega3, providing 300 mg Phosphatidylserine per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind: Cellulose (4 capsules per day). Open-label: PS-omega3</description>
          </group>
        </group_list>
        <measure>
          <title>Conners Rating Scale - School Version</title>
          <description>A questionnaire that assesses symptoms of ADHD in children and adolescents according to the DSM-IV guidelines. It consists of questions on classroom behavior. Based on the questionnaire results, subscales and global indexes are calculated, including restless-impulsive index, emotional lability index and hyperactive/impulsive subscale. The lowest scale score is 40 (best)and the highest is 90 (worse). Usually, a score below 62 is considered normal and a score above 62 is considered abnormal.</description>
          <population>The analysis includes per-protocol (PP) population. Out of the 162 children who completed the study, 15 children were excluded from PP analysis due to low compliance or protocol violation.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conners Global Index: restless impulsivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="1.04"/>
                    <measurement group_id="O2" value="-1.73" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conners Global index: Emotional Lability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.63" spread="1.18"/>
                    <measurement group_id="O2" value="-0.63" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity-impulsivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="1.09"/>
                    <measurement group_id="O2" value="-0.46" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conners Rating Scale - Home Version</title>
        <description>A questionnaire that assesses symptoms of ADHD in children and adolescents according to the DSM-IV guidelines. It consists of questions on the childs home behavior. Based on the questionnaire results, subscales and global indexes are calculated, including restless-impulsive index, emotional lability index and hyperactive/impulsive subscale. The lowest scale score is 40 (best)and the highest is 90 (worse). Usually, a score below 62 is considered normal and a score above 62 is considered abnormal.</description>
        <time_frame>change from baseline in conners raiting scale at 15 weeks</time_frame>
        <population>The analysis includes per-protocol (PP) population. Out of the 162 children who completed the study, 15 children were excluded from PP analysis due to low compliance or protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>PS Omega 3 Conjugate</title>
            <description>The daily dosage consisted of 4 capsules of PS-Omega3, providing 300 mg Phosphatidylserine per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind: Cellulose (4 capsules per day). Open-label: PS-omega3</description>
          </group>
        </group_list>
        <measure>
          <title>Conners Rating Scale - Home Version</title>
          <description>A questionnaire that assesses symptoms of ADHD in children and adolescents according to the DSM-IV guidelines. It consists of questions on the childs home behavior. Based on the questionnaire results, subscales and global indexes are calculated, including restless-impulsive index, emotional lability index and hyperactive/impulsive subscale. The lowest scale score is 40 (best)and the highest is 90 (worse). Usually, a score below 62 is considered normal and a score above 62 is considered abnormal.</description>
          <population>The analysis includes per-protocol (PP) population. Out of the 162 children who completed the study, 15 children were excluded from PP analysis due to low compliance or protocol violation.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Conner's Global restless-impulsivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.19" spread="1.00"/>
                    <measurement group_id="O2" value="-1.71" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conner's Global Index:Emotional lability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.54" spread="1.08"/>
                    <measurement group_id="O2" value="-5.56" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DSM-IV: Hperactivity impulsivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.23" spread="1.15"/>
                    <measurement group_id="O2" value="-2.62" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Strength and Difficulties Questionnaires - School Version</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Strength and Difficulties Questionnaires - Home Version</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Improvement</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Test of Variables of Attention (TOVA)</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Child Health Questionnaire (CHQ)- Parent-completed Form 50</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma and Red Blood Cells Fatty Acid Profile</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Monoamines Metabolism</title>
        <time_frame>on week 0, 15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Essential Fatty Acid (EFA)-Deficiency Symptoms</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barkley Side Effects Rating Scale (SERS)</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Blood Counts</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Parameters in Blood - Liver Functions (SGPT, SGOT, Total Bilirubin), Kidney Functions (BUN, Creatinine), Na, K, Cl, Ca</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile (Cholesterol, HDL, Triglycerides)</title>
        <time_frame>on weeks 0,15</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PS Omega 3 Conjugate</title>
          <description>The daily dosage consisted of 4 capsules of PS-Omega3, providing 300 mg Phosphatidylserine per day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Double-blind: Cellulose (4 capsules per day). Open-label: PS-omega3</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yael Richter Ph.D</name_or_title>
      <organization>Enzymotec Ltd</organization>
      <phone>+972 74 7177 177 ext 144</phone>
      <email>Yaelr@enzymotec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

